Sling ropes in $123m for oral thyroid eye disease drug - Pharmaceutical Technology

Sling is racing to market the first oral IGF-1R blocker, which would likely provide competition to Amgen’s Tepezza. Sling is racing to market the first oral IGF-1R blocker, which would likely provide competition to Amgen’s Tepezza. Sling is one of handful of biotechs targeting safer and more efficacious TED treatments. Credit: Vector mall/Shutterstock.com. Sling Therapeutics has raised $123m to propel its thyroid eye disease (TED) pill through a pivotal clinical trial. The funds, which were raised in a Series C round, will help the biotech evaluate linsitinib in an ongoing Phase III trial. In a separate announcement alongside the financing,…

Source: Pharmaceutical Technology